---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289210384.md"
description: "Seaport Therapeutics shares are trading higher after the company announced data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo in healthy volunteers."
datetime: "2026-06-09T14:55:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289210384.md)
  - [en](https://longbridge.com/en/news/289210384.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289210384.md)
generator: "portal-rs"
---

# 

Seaport Therapeutics shares are trading higher after the company announced data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo in healthy volunteers.

### Related Stocks

- [SPTX.US](https://longbridge.com/en/quote/SPTX.US.md)

## Related News & Research

- [Seaport Therapeutics CEO Daphne Zohar presents at Goldman Sachs Life Sciences Symposium](https://longbridge.com/en/news/298907083.md)
- [SPTX: Innovative oral neuropsychiatric therapies advance toward pivotal trials, backed by strong leadership](https://longbridge.com/en/news/298485305.md)
- [Seaport Therapeutics says Phase 1 trial shows GlyphAllo 375 mg does not impair next-morning driving vs placebo](https://longbridge.com/en/news/298444900.md)
- [HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX)](https://longbridge.com/en/news/298592169.md)
- [Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading](https://longbridge.com/en/news/297066497.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**